InsuJet Distribution Expands Across France
NuGen Medical Devices (TSXV: NGMD) has launched a French e-commerce platform www.insujet.fr for its needle-free insulin delivery device InsuJet. Developed with Sol-Millennium France, the platform offers product information, educational resources, and secure purchasing with optional nurse-led onboarding support.
The launch addresses a significant market opportunity in France, where 4.33 million people (6.3% of the population) lived with diabetes in 2022. Diabetes-related reimbursements in France increased from €7.6 billion in 2015 to over €10 billion in 2022. With 92% of Type 2 diabetes patients delaying insulin start due to needle anxiety, InsuJet aims to improve treatment adoption and reduce healthcare costs.
NuGen Medical Devices (TSXV: NGMD) ha lanciato una piattaforma di e-commerce francese www.insujet.fr per il suo dispositivo per la somministrazione di insulina senza ago InsuJet. Sviluppata in collaborazione con Sol-Millennium France, la piattaforma offre informazioni sul prodotto, risorse educative e un acquisto sicuro con supporto opzionale da parte di infermieri per l'introduzione all'uso.
Il lancio risponde a un'importante opportunità di mercato in Francia, dove nel 2022 4,33 milioni di persone (6,3% della popolazione) convivevano con il diabete. I rimborsi legati al diabete in Francia sono aumentati da 7,6 miliardi di euro nel 2015 a oltre 10 miliardi di euro nel 2022. Con il 92% dei pazienti con diabete di tipo 2 che ritarda l'inizio dell'insulina a causa della paura degli aghi, InsuJet punta a migliorare l'adozione del trattamento e a ridurre i costi sanitari.
NuGen Medical Devices (TSXV: NGMD) ha lanzado una plataforma de comercio electrónico francesa www.insujet.fr para su dispositivo de administración de insulina sin aguja InsuJet. Desarrollada junto con Sol-Millennium France, la plataforma ofrece información del producto, recursos educativos y compras seguras con soporte opcional guiado por enfermeros para la incorporación al uso.
El lanzamiento responde a una oportunidad significativa en el mercado francés, donde en 2022 vivían 4,33 millones de personas (6,3% de la población) con diabetes. Los reembolsos relacionados con la diabetes en Francia aumentaron de 7,6 mil millones de euros en 2015 a más de 10 mil millones en 2022. Con el 92% de los pacientes con diabetes tipo 2 que retrasan el inicio de la insulina debido al miedo a las agujas, InsuJet busca mejorar la adopción del tratamiento y reducir los costos sanitarios.
NuGen Medical Devices (TSXV: NGMD)는 프랑스 전자상거래 플랫폼 www.insujet.fr를 출시하여 바늘 없는 인슐린 투여 기기 InsuJet을 선보였습니다. Sol-Millennium France와 협력하여 개발된 이 플랫폼은 제품 정보, 교육 자료, 그리고 간호사가 지원하는 선택적 온보딩과 안전한 구매를 제공합니다.
이번 출시는 2022년 프랑스 인구의 6.3%인 433만 명이 당뇨병을 앓고 있는 중요한 시장 기회를 겨냥합니다. 프랑스의 당뇨병 관련 보험 환급액은 2015년 76억 유로에서 2022년 100억 유로 이상으로 증가했습니다. 바늘 공포로 인해 2형 당뇨병 환자의 92%가 인슐린 시작을 미루는 상황에서, InsuJet은 치료 수용을 개선하고 의료 비용을 줄이는 것을 목표로 합니다.
NuGen Medical Devices (TSXV : NGMD) a lancé une plateforme de commerce électronique française www.insujet.fr pour son dispositif d'administration d'insuline sans aiguille InsuJet. Développée avec Sol-Millennium France, la plateforme propose des informations sur le produit, des ressources éducatives et un achat sécurisé avec un accompagnement optionnel par des infirmiers pour l'intégration.
Ce lancement répond à une opportunité de marché importante en France, où 4,33 millions de personnes (6,3 % de la population) vivaient avec le diabète en 2022. Les remboursements liés au diabète en France sont passés de 7,6 milliards d'euros en 2015 à plus de 10 milliards en 2022. Avec 92 % des patients atteints de diabète de type 2 retardant le début de l'insuline à cause de la peur des aiguilles, InsuJet vise à améliorer l'adoption du traitement et à réduire les coûts de santé.
NuGen Medical Devices (TSXV: NGMD) hat eine französische E-Commerce-Plattform www.insujet.fr für sein nadel- und schmerzfreies Insulinabgabegerät InsuJet gestartet. In Zusammenarbeit mit Sol-Millennium France entwickelt, bietet die Plattform Produktinformationen, Bildungsressourcen und einen sicheren Kauf mit optionaler Unterstützung durch Pflegepersonal beim Einstieg.
Der Start adressiert eine bedeutende Marktchance in Frankreich, wo im Jahr 2022 4,33 Millionen Menschen (6,3 % der Bevölkerung) mit Diabetes lebten. Die erstatteten Kosten für Diabetes stiegen in Frankreich von 7,6 Milliarden Euro im Jahr 2015 auf über 10 Milliarden Euro im Jahr 2022. Da 92 % der Typ-2-Diabetiker aufgrund von Angst vor Nadeln den Beginn der Insulintherapie verzögern, zielt InsuJet darauf ab, die Behandlungseinführung zu verbessern und die Gesundheitskosten zu senken.
- Addresses large French diabetes market of 4.33 million patients
- Targets €10 billion diabetes reimbursement market in France
- Offers solution to 92% of Type 2 diabetes patients who delay insulin due to needle anxiety
- Includes comprehensive support with nurse-led onboarding program
- None.
NuGen Medical Devices Launches French InsuJet(TM) e-Commerce Platform, Delivering Needle-Free Insulin with On-Demand Clinical Support
Toronto, Ontario--(Newsfile Corp. - July 7, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, today unveiled www.insujet.fr — a dedicated French-language information and e-commerce site for InsuJet™, the Company's needle-free insulin-delivery device.
Developed with NuGen's exclusive distributor Sol-Millennium France, the platform gives people living with diabetes in France instant access to product details, educational resources, and secure online purchasing. At checkout, patients may opt for nurse-led onboarding that supports them all the way to seamless enrolment in the recurring consumables program — ensuring confident adoption and lasting adherence.
A Growing Market Need
According to France's National Health Insurance (Assurance Maladie), diabetes remains a critical — and growing — public-health challenge: in 2022, 4.33 million people were living with diabetes — a prevalence of 6.3 percent. The economic impact is escalating just as quickly: reimbursements tied to diabetes jumped from €7.6 billion in 2015 to more than €10 billion in 2022.1
Complications accounts for a significant share of diabetes-related healthcare costs because most of the 92 % of patients who have type 2 diabetes delay insulin start; 80 % of French physicians blame needle anxiety. By eliminating the needle for France's ~4 million type 2 diabetics, InsuJet™ promotes earlier insulin use and delivers substantial savings to the national health system.2
These figures highlight the urgent need for innovative, cost-effective solutions such as InsuJet's needle-free insulin-delivery technology.
About InsuJet™
Designed for adults and children (age 6+), InsuJet™ delivers standard U-100 insulin via a precise high-pressure micro-jet through the nozzle that penetrates the skin without needles.
Users experience less anxiety, no sharps-disposal burden, and simpler day-to-day diabetes management.
Clinical studies demonstrate faster insulin absorption, tighter glycaemic control, and higher patient satisfaction versus traditional needles - advances that directly address France's call for safer, more economical diabetes care.
Key Features:
- Durability — reusable for up to 5,000 injections (≈ 3.5 years at four injections per day)
- Universally compatible — works with any U-100 insulin in 3 mL cartridges, prefilled insulin pens, or 10 mL vials
- Needle-free convenience — eliminates sharps containers and related waste
- CE marked — compliant with European medical-device standards
- Broad usability — approved for adults and children aged six and over
Adoption and Interest from the Clinical Community:
The healthcare community has responded enthusiastically to the introduction of InsuJet™. Officially pre-launched at the 2025 Congress of the Société Francophone du Diabète (SFD) this past April, where it was named Innovation of the Year in Insulin Therapy, InsuJet™ attracted significant clinical interest. Numerous hospitals requested demonstrations, leading to two clinical evaluations at the Institut de Diabétologie et Nutrition du Centre (IDNC). These studies aim to support national reimbursement and further validate the clinical and economic benefits of needle-free insulin delivery.
About NuGen Medical Devices
NuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet™ system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide.
About Sol-Millennium Medical Group
Sol-Millennium Medical Group is a vertically integrated manufacturer of medical devices. With global operations and a commitment to deliver advanced, patient-centric healthcare technologies, Sol-Millennium Medical partners with healthcare providers to improve outcomes and build a healthier tomorrow for all.
Websites: insujet.com | insujet.fr | nugenmd.com
Instagram / X: @NuGenMD | LinkedIn: NuGenMD
Investor Relations: IR@nugenmd.com
For further information, please contact:
Liang Lin, Chief Executive Officer
+1 (833) 285-2666
ir@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
1 https://diabetesatlas.org/data-by-location/country/france/?
2 https://www.federationdesdiabetiques.org/information/diabete/chiffres-france?
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258027
FAQ
What is the market size for InsuJet's needle-free insulin device in France?
How does NuGen Medical Devices (NGMD) address needle anxiety in diabetes patients?
What support services does InsuJet offer French diabetes patients?
How has the diabetes-related healthcare cost evolved in France?
